S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Warren Buffett uses his annual letter to warn about Wall Street and recount Berkshire's successes
Best way to buy gold today (not what you'd think) (Ad)
MarketBeat Week in Review – 2/19 - 2/23
Taiwan giant chipmaker TSMC opens first plant in Japan as part of key global expansion
The perfect AI stock under $10 (Ad)
A collection of the insights Warren Buffett offered in his annual letter Saturday
West Africa bloc lifts coup sanctions on Niger in a new push for dialogue to resolve tensions
66,000% upside on tiny biotech? (Ad)
West Africa's ECOWAS bloc says it's lifting sanctions imposed on Niger over last year’s coup in a new push for dialogue
Macron booed by French farmers who blame him for not doing enough to support agriculture
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Warren Buffett uses his annual letter to warn about Wall Street and recount Berkshire's successes
Best way to buy gold today (not what you'd think) (Ad)
MarketBeat Week in Review – 2/19 - 2/23
Taiwan giant chipmaker TSMC opens first plant in Japan as part of key global expansion
The perfect AI stock under $10 (Ad)
A collection of the insights Warren Buffett offered in his annual letter Saturday
West Africa bloc lifts coup sanctions on Niger in a new push for dialogue to resolve tensions
66,000% upside on tiny biotech? (Ad)
West Africa's ECOWAS bloc says it's lifting sanctions imposed on Niger over last year’s coup in a new push for dialogue
Macron booed by French farmers who blame him for not doing enough to support agriculture
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Warren Buffett uses his annual letter to warn about Wall Street and recount Berkshire's successes
Best way to buy gold today (not what you'd think) (Ad)
MarketBeat Week in Review – 2/19 - 2/23
Taiwan giant chipmaker TSMC opens first plant in Japan as part of key global expansion
The perfect AI stock under $10 (Ad)
A collection of the insights Warren Buffett offered in his annual letter Saturday
West Africa bloc lifts coup sanctions on Niger in a new push for dialogue to resolve tensions
66,000% upside on tiny biotech? (Ad)
West Africa's ECOWAS bloc says it's lifting sanctions imposed on Niger over last year’s coup in a new push for dialogue
Macron booed by French farmers who blame him for not doing enough to support agriculture
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Warren Buffett uses his annual letter to warn about Wall Street and recount Berkshire's successes
Best way to buy gold today (not what you'd think) (Ad)
MarketBeat Week in Review – 2/19 - 2/23
Taiwan giant chipmaker TSMC opens first plant in Japan as part of key global expansion
The perfect AI stock under $10 (Ad)
A collection of the insights Warren Buffett offered in his annual letter Saturday
West Africa bloc lifts coup sanctions on Niger in a new push for dialogue to resolve tensions
66,000% upside on tiny biotech? (Ad)
West Africa's ECOWAS bloc says it's lifting sanctions imposed on Niger over last year’s coup in a new push for dialogue
Macron booed by French farmers who blame him for not doing enough to support agriculture

2 Biotech Stocks Showing Serious Relative Strength

2 Biotech Stocks Showing Serious Relative Strength

These Biotech Stocks Have Been Brilliant in 2022 Thus Far

Biotechnology is known to be one of the most volatile sectors in the market, which is why it’s been so interesting to see certain stocks in that area showing lots of relative strength during a volatile first few months of the year. Investors should note that it is especially important to choose carefully when adding exposure in this area of the market, as many of these companies are one FDA approval away from success and failure. A great way to potentially take advantage of the upside that biotech stocks have to offer is by narrowing your focus to companies that offer both a strong pipeline of promising new drugs and an existing line of successful drugs that help to keep the business financially stable.

A few names that fit that description have been some of the biggest outperformers in the market to start the year, which tells us a lot about what institutions and large investors are interested in buying during an uncertain period for both the economy and the market. There’s certainly a good chance that these current winners continue trending higher, particularly thanks to their lower exposure to geopolitical risks and sky-high upside should they receive approval for a new blockbuster drug. That’s why we’ve put together a brief overview of 2 biotech stocks that are showing serious relative strength to help you isolate some of the most intriguing names in the sector to target now.

Let’s take a deeper look below.

AbbVie (NYSE: ABBV)

First up is AbbVie, a very appealing biotech stock that has rallied over 20% year-to-date and continues to trend nicely. This is an appealing research-based biopharmaceutical company for several reasons, including a very consistent history of dividend increases. In fact, AbbVie is a dividend king, which means the company has boosted its payout for 50 consecutive years. The stock offers a 3.48% dividend yield and investors can likely count on the company to generate enough cash flows to support the dividend for years to come. That type of consistency and reliability is not easy to find these days, which is likely one reason why shares have been rallying.

It’s worth noting that AbbVie’s key drug Humira, which is used to treat rheumatoid arthritis and is the company’s largest product by revenue, will face a lot of biosimilar competition in 2023. With that said, AbbVie has been focused on developing new drugs that can drive growth and diversify its product base for the long term. Oncology drugs like Venclexta and Imbruvica are good examples, along with immunology drugs like Skyrizi and Rinvoq. The company also acquired Botox-manufacturer Allergan back in 2020 which should lead to strong organizational synergies and a more diverse revenue base for AbbVie over the long term, making this a very appealing option in the biopharma space.

Vertex Pharmaceuticals (NASDAQ: VRTX)

Cystic fibrosis is one of the most common and most serious genetic diseases in America, which is a great reason why Vertex Pharmaceuticals is an easy company to get behind. It’s a biotechnology company that is focused specifically on developing and commercializing therapies for the treatment of cystic fibrosis. Shares of this biotech stock have recently broken out to new all-time highs and are currently up over 22% year-to-date, which is strong outperformance compared to the S&P 500 thus far in 2022. Vertex is appealing given the company’s dominant position in CF drugs, as it has limited competition in that space and is eligible to treat roughly 90% of the CF population with its drugs Kalydeco, Orkambi, Symdeko, and Trikafta.

It’s also worth noting that Vertex has primarily discovered many of its new drug candidates in-house, which points toward the potential for future successful drugs in the company’s pipeline. Vertex’s revenue grew by 22% year-over-year in 2021, and with exciting new gene-editing candidates that are in phase 3 trials, the company could be on the verge of even more growth ahead. The bottom line is that Vertex Pharmaceuticals has been one of the strongest stocks in the market over the last few weeks, and with good reason. Investors looking for exposure to this intriguing company might want to consider adding shares on pullbacks in the coming sessions.
→ AI Stock Caught Trading Under Secret Name (From The Oxford Club) (Ad)

Should you invest $1,000 in Vertex Pharmaceuticals right now?

Before you consider Vertex Pharmaceuticals, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Vertex Pharmaceuticals wasn't on the list.

While Vertex Pharmaceuticals currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

5G Stocks: The Path Forward is Profitable Cover

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Companies Mentioned in This Article

CompanyMarketRank™Current PricePrice ChangeDividend YieldP/E RatioConsensus RatingConsensus Price Target
Vertex Pharmaceuticals (VRTX)
4.4121 of 5 stars
$430.11+0.8%N/A30.97Hold$417.27
AbbVie (ABBV)
4.8475 of 5 stars
$178.09+0.8%3.48%65.23Moderate Buy$175.36
Compare These Stocks  Add These Stocks to My Watchlist 


Featured Articles and Offers

Search Headlines: